Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report

Koksal, Iftihar; GÜMÜŞ, Mahmut; DEMİR, Ahmet Muzaffer; Örmeci, Necati; Kaymakoglu, Sabahattin; AYGEN, Bilgehan; TABAK, ÖMER FEHMİ; KARABAY, OĞUZ; KÖKSAL, Aydın Şeref

Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report

Bilgehan AYGEN, (Erciyes Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Kayseri, Türkiye)

Ahmet Muzaffer DEMİR, (Trakya Üniversitesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Hastalıkları Anabilim Dalı, Edirne, Türkiye)

Mahmut GÜMÜŞ, (İstanbul Medeniyet Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı Onkoloji Anabilim Dalı, İstanbul, Türkiye)

Oğuz KARABAY, (Sakarya Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim, Sakarya, Türkiye)

Sabahattin KAYMAKOĞLU, (İstanbul Üniversitesi, Tıp Fakültesi, Gastroenterohepatoloji Anabilim Dalı, İstanbul, Türkiye)

Aydın Şeref KÖKSAL, (Sakarya Üniversitesi, Tıp Fakültesi, Gastroenteroloji Ana Bilim Dalı, Sakarya, Türkiye)

İftihar KÖKSAL, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Trabzon, Türkiye)

Necati ÖRMECİ, (Ankara Üniversitesi, Tıp Fakültesi, Parazitoloji Anabilim Dalı, Ankara, Türkiye)

ÖMER FEHMİ TABAK (İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, İstanbul, Türkiye)

Turkish Journal of Gastroenterology

15 8

Yıl: 2018 Cilt: 29 Sayı: 3 Sayfa Aralığı: 259 - 269 Metin Dili: İngilizce İndeks Tarihi: 20-12-2018

Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report

Öz:

This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, pro-phylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to the risk of hepatitis B reactivation emergency. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.

Anahtar Kelime:

Konular: Gastroenteroloji ve Hepatoloji

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

TRDizin Dışındaki Atıf Sayıları

OpenCitations: 0

OpenAlex: 0

Crossref: 0

50. Paul S, Dickstein A, Saxena A, et al. Role of surface antibody in hep-atitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis. Hepatology 2017; 66: 379-88. [CrossRef]
49. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current con-cepts, management strategies and future directions. Gastroenterol-ogy 2017; 152: 1297-309. [CrossRef]
48. Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with im-mune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61: 703-11. [CrossRef]
47. Lok A, Bonis P, Esteban R. Hepatitis B virus reactivation associ-ated with immunosuppressive therapy. Up To Date. Available from: https://www.uptodate.com/contents/hepatitis-b-virus-reactiva-tion-associated-with-immunosuppressive-therapy.
46. Koksal I. Immunosuppressive Therapy and Hepatitis B Virus Re-activation. Viral Hepat J 2016; 22: 69-73. [CrossRef]
45. Ford R, Schwartz L, Dancey J. US Food and Drug Administra-tion; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER) et al. Guidance for indus-try: drug-induced liver injury-premarketing clinical evaluation. Eur J Cancer 2009; 45: 268-74. [CrossRef]
44. Terrault NA, Bzowej NH, Chang KM, et al. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261-83. [CrossRef]
43. Shang J, Wang H, Sun J, et al. A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allo-geneic hematopoietic stem cell transplantation recipients: a sin-gle-institutional experience. Bone Marrow Transplant 2016; 51: 581-6. [CrossRef]
42. Rapti IN, Hadziyannis SJ. Treatment of special populations with chronic hepatitis B infection. Expert Rev Gastroenterol Hepatol 2011; 5: 323-39. [CrossRef]
41. Pei SN, Chen CH. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemo-therapy with or without rituximab. Leuk Lymphoma 2015; 56: 1611-8
40. Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol 2015; 33: 2212-20. [CrossRef]
39. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology 2008; 47: 844-53. [CrossRef]
38. Weinbaum CM, Williams I, Mast EE,et al. Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 1-20.
37. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepa-tol Int 2016; 10: 1-98. [CrossRef]
36. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infec-tion. J Hepatol 2012; 57: 167-85. [CrossRef]
35. Reddy NM, Savani BN. Hepatitis B Reactivation in Patients with Hematological Malignancies and Stem Cell Transplantation. J Blood Lymph 2013; 4: 114.
34. Mikulska M, Nicolini L, Signori A, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infect 2014; 20: 694-701. [CrossRef]
33. Palmore TN, Shah NL, Loomba R, et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemo-therapy and immunosuppression. Clin Gastroenterol Hepatol 2009; 7: 1130-7. [CrossRef]
32. Martin ST, Cardwell SM, Nailor MD, et al. Hepatitis B Reactivation and Rituximab: A New Boxed Warning and Considerations for Solid Organ Transplantation. Am J Transplant 2014; 14: 788-96. [CrossRef]
31. Voican CS, Mir O, Loulergue P, et al. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treat-ment. Annals of Oncology 2016; 27: 2172-84. [CrossRef]
30. Hsu C, Tsou H-H, Lin S-J, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014; 59: 2092-100. [CrossRef]
29. Jang JW. Hepatitis B virus reactivation in patients with hepato-cellular carcinoma undergoing anti-cancer therapy. World J Gastro-enterol 2014; 20: 7675-85. [CrossRef]
28. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroen-terol Hepatol 2010; 25: 864-71. [CrossRef]
27. Gu HR, Shin D-Y, Choi H, et al. HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT. Blood Res 2015; 50: 51-3. [CrossRef]
26. Reynolds JA, Manch RA, Gish RG. Medical interventions associat-ed with HBV reactivation: Common and less common. Clinical Liver Disease 2015; 5: 32-4. [CrossRef]
25. Liu F, Dan J, Zhang Y, et al. Hepatitis B reactivation after treat-ment for HBV-related hepatocellular carcinoma: comparative analysis of radiofrequency ablation versus hepatic resection. Zhonghua Gan Zang Bing Za Zhi 2014; 22: 38-42.
24. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-44. [CrossRef]
23. Lee YH, Bae S-C, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013; 31: 118-21.
22. Calimeri T, Lopedote P, Repetto M, et al. Safety and tolerability of chemotherapy (CT) containing high doses of methotrexate (HD-MTX) and cytarabine (Ara-C) in patients with primary central ner-vous system lymphoma (PCNSL) and hepatitis B virus (HBV) infec-tion. Annals of Oncology 2017; 28: 355-71. [CrossRef]
21. Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int 2011; 31: 104-10. [CrossRef]
20. Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommenda-tions. World J Hepatol 2016; 8: 385-94. [CrossRef]
19. Reddy KR, Beavers KL, Hammond SP, et al. American Gastro-enterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppres-sive drug therapy. Gastroenterology 2015; 148: 215-9. [CrossRef]
18. Patulla V. Prevention of hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol 2016; 22: 219-37. [CrossRef]
17. Gonzalez SA, Perrillo RP. Hepatitis B virus reactivation in the set-ting of cancer chemotherapy and other immunosuppressive drug therapy. Clin Infect Dis 2016; 62: 306-13. [CrossRef]
16. Salpini R, Colagrossi L, Bellocchi MC, et al. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology 2015; 61: 823-33. [CrossRef]
15. Cho Y, Yu SJ, Cho EJ, et al. High titers of anti-HBs prevent ritux-imab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin’s lymphoma. J Med Virol 2016; 88: 1010-7. [CrossRef]
14. Pei SN, Ma MC, Wang MC, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012; 91: 1007-12. [CrossRef]
13. Borentain P, Colson P, Coso D, et al. Clinical and virological fac-tors associated with hepatitis B virus reactivation in HBsAg-nega-tive and anti-HBc antibodies-positive patients undergoing chemo-therapy and/or autologous stem cell transplantation for cancer. J Viral Hepat 2010; 17: 807-15. [CrossRef]
12. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus re-activation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307. [CrossRef]
11. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a pro-spective study. Gastroenterology 1991; 100: 182-8. [CrossRef]
10. Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactiva-tion in patients positive for HBV surface antigen undergoing autol-ogous hematopoietic cell transplantation. Blood 2002; 99: 2324-30
9. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk fac-tors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90:1306-11. [CrossRef]
8. Pattullo V. Hepatitis B reactivation in the setting of chemother-apy and immunosupression-prevention is better than cure. World J Hepatol 2015; 7: 954-67. [CrossRef]
7. Lok AS, MCMahon BJ. Chronic hepatitis B: update 2009. Hepatol-ogy 2009; 50: 661-2. [CrossRef]
6. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: 156-65. [CrossRef]
5. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Trans-fusion 2003; 43: 788-98. [CrossRef]
4. European Association for the Study of the Liver. EASL 2017 Clin-ical Practice Guidelines on the management of hepatitis B virus in-fection. J Hepatol 2017; 67: 370-98. [CrossRef]
3. Krugman S, Overby LR, Mushahwar IK, et al. Viral hepatitis, type B. Studies on natural history and prevention re-examined. N Engl J Med 1979; 300: 101-6. [CrossRef]
2. TÜİK 2016. Available from: URL: http://www.tuik.gov.tr/PreHaber-Bultenleri.do?id=24638.
1. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepa-titis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015; 21: 1020-6. [CrossRef]

APA	AYGEN B, DEMİR A, GÜMÜŞ M, KARABAY O, Kaymakoglu S, KÖKSAL A, Koksal I, Örmeci N, TABAK Ö (2018). Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. , 259 - 269.
Chicago	AYGEN Bilgehan,DEMİR Ahmet Muzaffer,GÜMÜŞ Mahmut,KARABAY OĞUZ,Kaymakoglu Sabahattin,KÖKSAL Aydın Şeref,Koksal Iftihar,Örmeci Necati,TABAK ÖMER FEHMİ Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. (2018): 259 - 269.
MLA	AYGEN Bilgehan,DEMİR Ahmet Muzaffer,GÜMÜŞ Mahmut,KARABAY OĞUZ,Kaymakoglu Sabahattin,KÖKSAL Aydın Şeref,Koksal Iftihar,Örmeci Necati,TABAK ÖMER FEHMİ Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. , 2018, ss.259 - 269.
AMA	AYGEN B,DEMİR A,GÜMÜŞ M,KARABAY O,Kaymakoglu S,KÖKSAL A,Koksal I,Örmeci N,TABAK Ö Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. . 2018; 259 - 269.
Vancouver	AYGEN B,DEMİR A,GÜMÜŞ M,KARABAY O,Kaymakoglu S,KÖKSAL A,Koksal I,Örmeci N,TABAK Ö Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. . 2018; 259 - 269.
IEEE	AYGEN B,DEMİR A,GÜMÜŞ M,KARABAY O,Kaymakoglu S,KÖKSAL A,Koksal I,Örmeci N,TABAK Ö "Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report." , ss.259 - 269, 2018.
ISNAD	AYGEN, Bilgehan vd. "Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report". (2018), 259-269.

APA	AYGEN B, DEMİR A, GÜMÜŞ M, KARABAY O, Kaymakoglu S, KÖKSAL A, Koksal I, Örmeci N, TABAK Ö (2018). Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turkish Journal of Gastroenterology, 29(3), 259 - 269.
Chicago	AYGEN Bilgehan,DEMİR Ahmet Muzaffer,GÜMÜŞ Mahmut,KARABAY OĞUZ,Kaymakoglu Sabahattin,KÖKSAL Aydın Şeref,Koksal Iftihar,Örmeci Necati,TABAK ÖMER FEHMİ Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turkish Journal of Gastroenterology 29, no.3 (2018): 259 - 269.
MLA	AYGEN Bilgehan,DEMİR Ahmet Muzaffer,GÜMÜŞ Mahmut,KARABAY OĞUZ,Kaymakoglu Sabahattin,KÖKSAL Aydın Şeref,Koksal Iftihar,Örmeci Necati,TABAK ÖMER FEHMİ Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turkish Journal of Gastroenterology, vol.29, no.3, 2018, ss.259 - 269.
AMA	AYGEN B,DEMİR A,GÜMÜŞ M,KARABAY O,Kaymakoglu S,KÖKSAL A,Koksal I,Örmeci N,TABAK Ö Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turkish Journal of Gastroenterology. 2018; 29(3): 259 - 269.
Vancouver	AYGEN B,DEMİR A,GÜMÜŞ M,KARABAY O,Kaymakoglu S,KÖKSAL A,Koksal I,Örmeci N,TABAK Ö Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turkish Journal of Gastroenterology. 2018; 29(3): 259 - 269.
IEEE	AYGEN B,DEMİR A,GÜMÜŞ M,KARABAY O,Kaymakoglu S,KÖKSAL A,Koksal I,Örmeci N,TABAK Ö "Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report." Turkish Journal of Gastroenterology, 29, ss.259 - 269, 2018.
ISNAD	AYGEN, Bilgehan vd. "Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report". Turkish Journal of Gastroenterology 29/3 (2018), 259-269.